4. Rodger AJ

Cambiano V

Bruun T

et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 316 : 171-181 View in Article Scopus (537)

PubMed

Crossref

Google Scholar

5. d'Arminio Monforte A

Sabin CA

Phillips A

et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 165 : 416-423 View in Article Scopus (115)

PubMed

Crossref

Google Scholar

6. Saez-Cirion A

Bacchus C

Hocqueloux L

et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 9 : e1003211 View in Article Scopus (593)

PubMed

Crossref

Google Scholar

7. Lundgren JD

Babiker AG

Gordin F

et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 373 : 795-807 View in Article Scopus (1)

PubMed

Crossref

Google Scholar

9. Piot P

Quinn TC Response to the AIDS pandemic—a global health model. N Engl J Med. 368 : 2210-2218 View in Article Scopus (97)

Crossref

Google Scholar

11. Hraber P

Seaman MS

Bailer RT

Mascola JR

Montefiori DC

Korber BT Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS. 28 : 163-169 View in Article Scopus (208)

PubMed

Crossref

Google Scholar

12. Simek MD

Rida W

Priddy FH

et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 83 : 7337-7348 View in Article Scopus (405)

PubMed

Crossref

Google Scholar

13. Binley JM

Lybarger EA

Crooks ET

et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 82 : 11651-11668 View in Article Scopus (289)

PubMed

Crossref

Google Scholar

15. Scheid JF

Mouquet H

Ueberheide B

et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 333 : 1633-1637 View in Article Scopus (724)

PubMed

Crossref

Google Scholar

16. Walker LM

Phogat SK

Chan-Hui PY

et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326 : 285-289 View in Article Scopus (1225)

PubMed

Crossref

Google Scholar

17. Wu X

Yang ZY

Li Y

et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329 : 856-861 View in Article Scopus (1142)

PubMed

Crossref

Google Scholar

18. Kong R

Xu K

Zhou T

et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science. 352 : 828-833 View in Article Scopus (147)

PubMed

Crossref

Google Scholar

20. Huang J

Kang BH

Pancera M

et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 515 : 138-142 View in Article Scopus (275)

PubMed

Crossref

Google Scholar

22. Mouquet H

Scharf L

Euler Z

et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA. 109 : E3268-E3277 View in Article Scopus (314)

PubMed

Crossref

Google Scholar

24. Moore PL

Gray ES

Wibmer CK

et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 18 : 1688-1692 View in Article Scopus (204)

PubMed

Crossref

Google Scholar

25. Burton DR

Pyati J

Koduri R

et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266 : 1024-1027 View in Article Scopus (934)

PubMed

Crossref

Google Scholar

26. Rudicell RS

Kwon YD

Ko SY

et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 88 : 12669-12682 View in Article Scopus (161)

PubMed

Crossref

Google Scholar

27. Kong R

Louder MK

Wagh K

et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol. 89 : 2659-2671 View in Article Scopus (79)

PubMed

Crossref

Google Scholar

28. Diskin R

Scheid JF

Marcovecchio PM

et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 334 : 1289-1293 View in Article Scopus (274)

PubMed

Crossref

Google Scholar

29. Wu X

Zhou T

Zhu J

et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 333 : 1593-1602 View in Article Scopus (600)

PubMed

Crossref

Google Scholar

30. Falkowska E

Ramos A

Feng Y

et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol. 86 : 4394-4403 View in Article Scopus (87)

PubMed

Crossref

Google Scholar

31. Corti D

Langedijk JP

Hinz A

et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PloS One. 5 : e8805 View in Article Scopus (347)

PubMed

Crossref

Google Scholar

32. Gorny MK

Xu JY

Karwowska S

Buchbinder A

Zolla-Pazner S Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol. 150 : 635-643 View in Article PubMed

Google Scholar

33. Bonsignori M

Montefiori DC

Wu X

et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol. 86 : 4688-4692 View in Article Scopus (124)

PubMed

Crossref

Google Scholar

34. Doria-Rose NA

Bhiman JN

Roark RS

et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J Virol. 90 : 76-91 View in Article Scopus (96)

PubMed

Crossref

Google Scholar

35. Sok D

van Gils MJ

Pauthner M

et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci USA. 111 : 17624-17629 View in Article Scopus (170)

PubMed

Crossref

Google Scholar

36. Trkola A

Purtscher M

Muster T

et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 70 : 1100-1108 View in Article PubMed

Crossref

Google Scholar

37. Doores KJ

Fulton Z

Huber M

Wilson IA

Burton DR Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol. 84 : 10690-10699 View in Article Scopus (61)

PubMed

Crossref

Google Scholar

38. Julien JP

Sok D

Khayat R

et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 9 : e1003342 View in Article Scopus (190)

PubMed

Crossref

Google Scholar

40. Pejchal R

Doores KJ

Walker LM

et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 334 : 1097-1103 View in Article Scopus (495)

PubMed

Crossref

Google Scholar

41. Kong L

Lee JH

Doores KJ

et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol. 20 : 796-803 View in Article Scopus (236)

PubMed

Crossref

Google Scholar

42. Buchacher A

Predl R

Strutzenberger K

et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses. 10 : 359-369 View in Article Scopus (443)

PubMed

Crossref

Google Scholar

43. Muster T

Steindl F

Purtscher M

et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 67 : 6642-6647 View in Article PubMed

Crossref

Google Scholar

44. Zwick MB

Labrijn AF

Wang M

et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 75 : 10892-10905 View in Article Scopus (669)

PubMed

Crossref

Google Scholar

47. Klein F

Gaebler C

Mouquet H

et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med. 209 : 1469-1479 View in Article Scopus (119)

PubMed

Crossref

Google Scholar

48. Lee JH

Leaman DP

Kim AS

et al. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nature Commun. 6 : 8167 View in Article Scopus (46)

PubMed

Crossref

Google Scholar

50. Hessell AJ

Hangartner L

Hunter M

et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 449 : 101-104 View in Article Scopus (624)

PubMed

Crossref

Google Scholar

51. Ahmad R

Sindhu ST

Toma E

et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol. 21 : 227-233 View in Article Scopus (118)

PubMed

Crossref

Google Scholar

52. Nag P

Kim J

Sapiega V

et al. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis. 190 : 1970-1978 View in Article Scopus (70)

PubMed

Crossref

Google Scholar

54. Hessell AJ

Jaworski JP

Epson E

et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med. 22 : 362-368 View in Article Scopus (90)

PubMed

Crossref

Google Scholar

55. Bolton DL

Pegu A

Wang K

et al. Human immunodeficiency virus type 1 monoclonal antibodies suppress acute simian-human immunodeficiency virus viremia and limit seeding of cell-associated viral reservoirs. J Virol. 90 : 1321-1332 View in Article Scopus (41)

PubMed

Crossref

Google Scholar

57. Lu CL

Murakowski DK

Bournazos S

et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science. 352 : 1001-1004 View in Article Scopus (160)

PubMed

Crossref

Google Scholar

58. Jaworski JP

Kobie J

Brower Z

et al. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J Virol. 87 : 10447-10459 View in Article Scopus (27)

PubMed

Crossref

Google Scholar

59. Ng CT

Jaworski JP

Jayaraman P

et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med. 16 : 1117-1119 View in Article Scopus (106)

PubMed

Crossref

Google Scholar

60. Schoofs T

Klein F

Braunschweig M

et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 352 : 997-1001 View in Article Scopus (144)

PubMed

Crossref

Google Scholar

62. Michaud HA

Gomard T

Gros L

et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog. 6 : e1000948 View in Article Scopus (35)

PubMed

Crossref

Google Scholar

63. Moldt B

Rakasz EG

Schultz N

et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA. 109 : 18921-18925 View in Article Scopus (308)

PubMed

Crossref

Google Scholar

64. Pegu A

Yang ZY

Boyington JC

et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 6 : 243ra88 View in Article Scopus (154)

PubMed

Crossref

Google Scholar

66. Shingai M

Donau OK

Plishka RJ

et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med. 211 : 2061-2074 View in Article Scopus (191)

PubMed

Crossref

Google Scholar

67. Moldt B

Le KM

Carnathan DG

et al. Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. AIDS. 30 : 1543-1551 View in Article Scopus (33)

PubMed

Crossref

Google Scholar

70. Klein F

Halper-Stromberg A

Horwitz JA

et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 492 : 118-122 View in Article Scopus (346)

PubMed

Crossref

Google Scholar

72. Bar KJ

Sneller MC

Harrison LJ

et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 375 : 2037-2050 View in Article Scopus (182)

PubMed

Crossref

Google Scholar

74. Ledgerwood JE

Coates EE

Yamshchikov G

et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 182 : 289-301 View in Article Scopus (126)

PubMed

Crossref

Google Scholar

75. Lynch RM

Boritz E

Coates EE

et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 7 : 319ra206 View in Article Scopus (212)

PubMed

Crossref

Google Scholar

78. Mayer KH

Seaton KE

Huang Y

et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial. PLoS Med. 14 : e1002435 View in Article Scopus (37)

PubMed

Crossref

Google Scholar

79. Gilbert PB

Juraska M

deCamp AC

et al. Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials. Stat Commun Infect Dis. 9 : 20160001 View in Article PubMed

Google Scholar

80. Cunningham CK Safety and pharmacokinetics of a potent anti-HIV monoclonal antibody, VRC01, in HIV-exposed newborns. http://www.croiconference.org/sessions/safety-pharmacokinetics-monoclonal-antibody-vrc01-hiv-exposed-newborns Date: 2017 Date accessed: September 11, 2018 View in Article Google Scholar

81. Wagh K

Bhattacharya T

Williamson C

et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog. 12 : e1005520 View in Article Scopus (72)

PubMed

Crossref

Google Scholar

82. Derking R

Ozorowski G

Sliepen K

et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 11 : e1004767 View in Article Scopus (68)

PubMed

Crossref

Google Scholar

84. Xu L

Pegu A

Rao E

et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 358 : 85-90 View in Article Scopus (124)

PubMed

Crossref

Google Scholar

86. Ko SY

Pegu A

Rudicell RS

et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 514 : 642-645 View in Article Scopus (165)

PubMed

Crossref

Google Scholar

87. Gaudinski MR

Coates EE

Houser KV

et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 15 : e1002493 View in Article Scopus (55)

PubMed

Crossref

Google Scholar

89. Boesch AW

Alter G

Ackerman ME Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. Curr Opin HIV AIDS. 10 : 160-169 View in Article Scopus (15)

PubMed

Crossref

Google Scholar